Product Images Lisdexamfetamine Dimesylate
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 10 images provide visual information about the product associated with Lisdexamfetamine Dimesylate NDC 72162-2455 by Bryant Ranch Prepack, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Label - lbl721622455
This text is a package insert for Lisdexamfetamine capsules containing details about the medication, including the dosage, storage instructions, and manufacturer information. It is recommended to scan the QR code for dosage information and dispense the capsules to patients as directed. The medication should be stored within a certain temperature range and kept in a tight, light-resistant container. Remember to keep the capsules out of reach of children.*
Chemical Structure - lisdexcaps 01
Figure 1 - lisdexcaps 02
This text seems to provide information related to a special population, specifically focusing on gender (male/female), age range (65-75 years), renal impairment levels (mild, moderate, severe, end-stage renal disease), and a fold change with a confidence interval of 90%. It also mentions a change relative to reference. This data appears to be part of a research or study involving a specific population and their renal health status.*
Figure 2 - lisdexcaps 03
Figure 3 - lisdexcaps 04
This is "Interacting drug" information regarding various medications and their interaction with different enzymes. It includes drugs like Guanfacine, Venlafaxine, Caffeine, Dextromethorphan, Omeprazole, and Midazolam, along with their respective enzyme substrates. The data displayed includes Pharmacokinetic parameters like Cmax and AUC and compares them with fold change and 90% CI.*
Figure 4 - lisdexcaps 05
Figure 5 - lisdexcaps 06
Figure 6 - lisdexcaps 07
This information shows the LS Mean (SE) PERMP Total Scores over a period of time for Phacebo (presumably placebo) and Lisdexamfetamine. The scores are measured at different time points post-dose, with data points at 4, 8, 12, and 14 hours. The scale of the scores ranges from 250 to 330.*
Figure 7 - lisdexcaps 08
This text shows the proportion of subjects with relapse/treatment failure (%) over time (days after randomization) for Lisdexamfetamine.*
Figure 8 - lisdexcaps 09
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
